The Virology Core will be responsible for the generating full-length viral genome sequences from the majority of study subjects in this U19 through a highly organized, and high-throughput 454 sequencing approach. As these data can be generated rapidly, these data will also serve to identify subjects and epitopes for downstream analysis for the proposed specific studies on outlined in Projects 1-4. To rule out any confounding effects on our study design of possible virus-specific interferon resistance associated with prior interferon therapy failure, the Virology Core will also determine whether there is any evidence of genotypic resistance to interferon in subjects previously having failed interferon therapy. Specifically, the Virology Core will:
Aim 1 : Characterize full genome viral sequences from all HCV+ study subjects to identify epitope-specific sequence data for downstream phenotype and functional assays.
Aim 2 : Determine whether subjects who failed to achieve prior sustained virologic response (SVR) under interferon and ribavirin therapy exhibit any IFN genotypic resistance markers

Public Health Relevance

Knowledge of each subject's viral sequence will be important to ensure that the proper reagents (peptides, tetramers) are used for each assay, and to enable where needed autologous peptide screening to known T cell epitopes, but even more importantly to also ensure that viral escape has not altered the immune response or phenotype of responding cells to be included in analyses. It will also be important to demonstrate that prior interferon treatment failure is not due to development of interferon resistance.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97
Fergusson, J R; Hühn, M H; Swadling, L et al. (2016) CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol 9:401-13
Attanasio, John; Wherry, E John (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity 44:1052-68
Llibre, Alba; López-Macías, Constantino; Marafioti, Teresa et al. (2016) LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol 196:2085-94
Kurioka, Ayako; Walker, Lucy J; Klenerman, Paul et al. (2016) MAIT cells: new guardians of the liver. Clin Transl Immunology 5:e98
van Wilgenburg, Bonnie; Scherwitzl, Iris; Hutchinson, Edward C et al. (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653
Jeffery, Hannah C; van Wilgenburg, Bonnie; Kurioka, Ayako et al. (2016) Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 64:1118-27
Kelly, Christabel; Swadling, Leo; Capone, Stefania et al. (2016) Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63:1455-70
Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian et al. (2016) HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 6:22487
Swadling, Leo; Halliday, John; Kelly, Christabel et al. (2016) Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel) 4:

Showing the most recent 10 out of 128 publications